HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
10 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
TCAP
titin-cap
Chromosome 17 Β· 17q12
NCBI Gene: 8557Ensembl: ENSG00000173991.6HGNC: HGNC:11610UniProt: A2TDC0
76PubMed Papers
22Diseases
0Drugs
35Pathogenic Variants
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
cardiac muscle cell developmenttitin bindingBMP bindingsarcomerogenesishypertrophic cardiomyopathy 25autosomal recessive limb-girdle muscular dystrophy type 2Glimb-girdle muscular dystrophyfamilial hypertrophic cardiomyopathy
✦AI Summary

TCAP (titin-cap/telethonin) is a sarcomeric Z-disc protein essential for muscle assembly and mechanical sensing. Primary Function: TCAP mediates antiparallel assembly of titin molecules at the sarcomeric Z-disc and functions as a mechanosensory component within the titin/Tcap/muscle LIM protein (MLP) complex 1. Mechanism: TCAP interacts with titin, MLP, and calsarcin-1 at the Z-disc, where it tethers calcineurin to transduce mechanical stretch signals during sarcomeric contraction 1. TCAP expression is developmentally regulated and enriched in skeletal and cardiac muscle tissue 2. Disease Relevance: TCAP mutations cause distinct cardiomyopathies and limb-girdle muscular dystrophy (LGMD-2G/LGMD-R7). HCM-associated mutations (T137I, R153H) augment Tcap-titin interactions, while DCM-associated mutations (E132Q, R87Q) impair Z-disc component interactions 1. LGMD-2G represents the predominant TCAP-related phenotype 3, with the c.26_33dupAGGTGTCG mutation being frequent in Asian populations 4. Clinical Significance: TCAP dysfunction compromises sarcomere structural integrity and mechanotransduction, causing progressive muscle weakness and cardiac dysfunction. Recent evidence suggests PXR-mediated TCAP upregulation promotes cardiac recovery post-myocardial infarction 5, offering therapeutic potential for ischemic heart disease.

Sources cited
1
TCAP mediates titin assembly at Z-disc and serves as part of the titin/Tcap/MLP mechanical stretch sensor complex; mutations differentially affect Z-disc protein interactions in HCM versus DCM
PMID: 15582318
2
TCAP is a developmentally regulated sarcomeric protein with abundant expression in skeletal and cardiac muscle tissue
PMID: 19488834
3
TCAP pathogenic mutations cause LGMD-2G as the most prevalent phenotype, along with DCM, HCM, and other manifestations
PMID: 37752589
4
TCAP mutations, particularly c.26_33dupAGGTGTCG, are the most frequent LGMD-R7/LGMD2G mutations in Chinese patients
PMID: 37974208
5
TCAP expression is promoted by PXR activation and contributes to post-myocardial infarction cardiac repair and angiogenesis
PMID: 38889638
6
TCAP is part of the sarcomere mechanosensory complex with regulated expression during muscle training
PMID: 31426609
Disease Associationsβ“˜22
hypertrophic cardiomyopathy 25Open Targets
0.76Strong
autosomal recessive limb-girdle muscular dystrophy type 2GOpen Targets
0.74Strong
limb-girdle muscular dystrophyOpen Targets
0.64Moderate
familial hypertrophic cardiomyopathyOpen Targets
0.55Moderate
Abnormality of the cardiovascular systemOpen Targets
0.53Moderate
dilated cardiomyopathyOpen Targets
0.51Moderate
autosomal recessive limb-girdle muscular dystrophyOpen Targets
0.46Moderate
Abnormality of the musculatureOpen Targets
0.44Moderate
familial isolated dilated cardiomyopathyOpen Targets
0.38Weak
Elevated circulating creatine kinase concentrationOpen Targets
0.34Weak
hypertrophic cardiomyopathyOpen Targets
0.34Weak
cardiomyopathyOpen Targets
0.33Weak
isolated asymptomatic elevation of creatine phosphokinaseOpen Targets
0.33Weak
Rare familial disorder with hypertrophic cardiomyopathyOpen Targets
0.18Weak
hypertrophic cardiomyopathy 1Open Targets
0.16Weak
hypertrophic cardiomyopathy 4Open Targets
0.12Weak
Left ventricular noncompaction cardiomyopathyOpen Targets
0.12Weak
ventricular tachycardiaOpen Targets
0.12Weak
Wolff-Parkinson-White SyndromeOpen Targets
0.11Weak
congestive heart failureOpen Targets
0.08Suggestive
Cardiomyopathy, familial hypertrophic, 25UniProt
Muscular dystrophy, limb-girdle, autosomal recessive 7UniProt
Pathogenic Variants35
NM_003673.4(TCAP):c.26_33dup (p.Glu12fs)Pathogenic
not provided|Hypertrophic cardiomyopathy 25;Primary familial hypertrophic cardiomyopathy|Autosomal recessive limb-girdle muscular dystrophy type 2G|Cardiovascular phenotype
β˜…β˜…β˜†β˜†2025β†’ Residue 12
NM_003673.4(TCAP):c.157C>T (p.Gln53Ter)Pathogenic
Autosomal recessive limb-girdle muscular dystrophy type 2G|Hypertrophic cardiomyopathy 25|Primary dilated cardiomyopathy|Hypertrophic cardiomyopathy 25;Primary familial hypertrophic cardiomyopathy|Autosomal recessive limb-girdle muscular dystrophy type 2G;Hypertrophic cardiomyopathy 25|Cardiovascular phenotype
β˜…β˜…β˜†β˜†2025β†’ Residue 53
NM_003673.4(TCAP):c.66G>A (p.Trp22Ter)Pathogenic
not provided|Hypertrophic cardiomyopathy 25;Primary familial hypertrophic cardiomyopathy|Hypertrophic cardiomyopathy 25|Cardiovascular phenotype|Hypertrophic cardiomyopathy 25;Autosomal recessive limb-girdle muscular dystrophy type 2G
β˜…β˜…β˜†β˜†2025β†’ Residue 22
NM_003673.4(TCAP):c.75G>A (p.Trp25Ter)Pathogenic
Autosomal recessive limb-girdle muscular dystrophy type 2G|Hypertrophic cardiomyopathy 25;Primary familial hypertrophic cardiomyopathy
β˜…β˜…β˜†β˜†2025β†’ Residue 25
NM_003673.4(TCAP):c.110_110+1delPathogenic
Autosomal recessive limb-girdle muscular dystrophy type 2G|Hypertrophic cardiomyopathy 25;Primary familial hypertrophic cardiomyopathy|Cardiovascular phenotype|Autosomal recessive limb-girdle muscular dystrophy type 2G;Hypertrophic cardiomyopathy 25
β˜…β˜…β˜†β˜†2024
NM_003673.4(TCAP):c.110+5G>TLikely pathogenic
not provided|Autosomal recessive limb-girdle muscular dystrophy type 2G
β˜…β˜…β˜†β˜†2024
NM_003673.4(TCAP):c.90_91del (p.Ser31fs)Pathogenic
Elevated circulating creatine kinase concentration|Abnormality of the musculature|Autosomal recessive limb-girdle muscular dystrophy type 2G
β˜…β˜…β˜†β˜†2023β†’ Residue 31
NM_003673.4(TCAP):c.14_15del (p.Glu5fs)Likely pathogenic
Abnormality of the musculature|Autosomal recessive limb-girdle muscular dystrophy type 2G
β˜…β˜…β˜†β˜†2023β†’ Residue 5
NM_003673.4(TCAP):c.103G>T (p.Glu35Ter)Pathogenic
not provided|Hypertrophic cardiomyopathy 25;Primary familial hypertrophic cardiomyopathy
β˜…β˜…β˜†β˜†2022β†’ Residue 35
NM_003673.4(TCAP):c.34dup (p.Glu12fs)Pathogenic
Autosomal recessive limb-girdle muscular dystrophy type 2G|Abnormality of the musculature|Primary familial hypertrophic cardiomyopathy;Hypertrophic cardiomyopathy 25
β˜…β˜…β˜†β˜†2021β†’ Residue 12
NM_003673.4(TCAP):c.43_49dup (p.Arg17delinsLeuTer)Pathogenic
not provided|Hypertrophic cardiomyopathy 25;Primary familial hypertrophic cardiomyopathy
β˜…β˜…β˜†β˜†2020β†’ Residue 17
NM_003673.4(TCAP):c.165del (p.Gln56fs)Likely pathogenic
Autosomal recessive limb-girdle muscular dystrophy type 2G
β˜…β˜†β˜†β˜†2025β†’ Residue 56
NM_003673.4(TCAP):c.45_46del (p.Cys15_Glu16delinsTer)Pathogenic
Hypertrophic cardiomyopathy 25;Primary familial hypertrophic cardiomyopathy
β˜…β˜†β˜†β˜†2025β†’ Residue 15
NM_003673.4(TCAP):c.152_153insAA (p.Tyr51Ter)Pathogenic
Hypertrophic cardiomyopathy 25;Primary familial hypertrophic cardiomyopathy
β˜…β˜†β˜†β˜†2025β†’ Residue 51
NM_003673.4(TCAP):c.215del (p.Gly72fs)Pathogenic
Cardiovascular phenotype
β˜…β˜†β˜†β˜†2025β†’ Residue 72
NM_003673.4(TCAP):c.1A>T (p.Met1Leu)Likely pathogenic
Primary familial hypertrophic cardiomyopathy;Hypertrophic cardiomyopathy 25
β˜…β˜†β˜†β˜†2025β†’ Residue 1
NM_003673.4(TCAP):c.154dup (p.His52fs)Pathogenic
Primary familial hypertrophic cardiomyopathy;Hypertrophic cardiomyopathy 25
β˜…β˜†β˜†β˜†2025β†’ Residue 52
NM_003673.4(TCAP):c.136_137del (p.Gln46fs)Pathogenic
Hypertrophic cardiomyopathy 25;Primary familial hypertrophic cardiomyopathy
β˜…β˜†β˜†β˜†2025β†’ Residue 46
NM_003673.4(TCAP):c.110+5G>APathogenic
Primary familial hypertrophic cardiomyopathy;Hypertrophic cardiomyopathy 25
β˜…β˜†β˜†β˜†2025
NM_003673.4(TCAP):c.34del (p.Glu12fs)Pathogenic
Primary familial hypertrophic cardiomyopathy;Hypertrophic cardiomyopathy 25
β˜…β˜†β˜†β˜†2024β†’ Residue 12
View on ClinVar β†—
Related Genes
OBSCNProtein interaction99%MYOZ1Protein interaction99%MYL1Protein interaction97%ACTN2Protein interaction95%ACTN3Protein interaction95%MYBPC3Protein interaction95%
Tissue Expression6 tissues
Heart
100%
Lung
0%
Ovary
0%
Liver
0%
Brain
0%
Bone Marrow
0%
Gene Interaction Network
Click a node to explore
TCAPOBSCNMYOZ1MYL1ACTN2ACTN3MYBPC3
PROTEIN STRUCTURE
Preparing viewer…
PDB1YA5 Β· 2.44 Γ… Β· X-ray
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
1.37LoF Tolerant
pLIβ“˜
0.00Tolerant
Observed/Expected LoF0.88 [0.58–1.37]
RankingsWhere TCAP stands among ~20K protein-coding genes
  • #6,293of 20,598
    Most Researched76
  • #1,677of 5,498
    Most Pathogenic Variants35
  • #14,320of 17,882
    Most Constrained (LOEUF)1.37
Genes detectedTCAP
Sources retrieved10 papers
Response timeβ€”
πŸ“„ Sources
10β–Ό
1
PMID: 20301486
1.00
2
A 20-year Clinical and Genetic Neuromuscular Cohort Analysis in Lebanon: An International Effort.
PMID: 34602496
J Neuromuscul Dis Β· 2022
0.90
3
Clinical and Genomic Evaluation of 207 Genetic Myopathies in the Indian Subcontinent.
PMID: 33250842
Front Neurol Β· 2020
0.80
4
SGLT2 inhibitor Dapagliflozin alleviates cardiac dysfunction and fibrosis after myocardial infarction by activating PXR and promoting angiogenesis.
PMID: 38889638
Biomed Pharmacother Β· 2024
0.70
5
Tcap gene mutations in hypertrophic cardiomyopathy and dilated cardiomyopathy.
PMID: 15582318
J Am Coll Cardiol Β· 2004
0.60